12/17/2020

IVI-SK’s new typhoid conjugate vaccine meets primary endpoints in phase III study in Nepal

Primary analysis also confirms safety of Vi-DT   December 17, 2020 – SEOUL, South Korea – Vi-DT typhoid conjugate vaccine, developed jointly by the International Vaccine Institute (IVI) and SK bioscience, has met the primary endpoints in a phase III study in Nepal. The primary […]
07/26/2021

THECA consortium begins Vi-TT typhoid conjugate vaccine phase IV effectiveness study in Ghana

July 26, 2021 – SEOUL, Republic of Korea – The International Vaccine Institute (IVI) announced today the start of a cluster-randomized, controlled Phase IV trial to assess the effectiveness of Typbar® typhoid conjugate vaccine (TCV) in preventing typhoid infection in children in Asante Akim, Ghana […]
DONATE